Core Insights - The company reported its H1 2025 financial results, with revenue, net profit attributable to shareholders, and net profit excluding non-recurring items at 1.25 billion, 450 million, and 440 million yuan respectively, showing a year-on-year change of -3.6%, +10%, and +11.1% [1] - In Q2 2025, the company achieved revenue, net profit attributable to shareholders, and net profit excluding non-recurring items of 670 million, 250 million, and 250 million yuan respectively, with year-on-year changes of +1%, +7%, and +8.1%, and quarter-on-quarter changes of +16.3%, +30.2%, and +29.1% [1] - The revenue growth in Q2 was primarily impacted by maintenance activities, while structural optimization contributed to improved profitability [1] Financial Performance - H1 2025 basic warehouse business revenue increased by 4.3% year-on-year, demonstrating resilience [1] - Revenue growth in specific sectors for H1 2025 included metals (+22.8%), life sciences (+12.4%), water (+11.3%), while sectors like environmental protection (-43.2%), food (+30.6%), and chemicals (-29.7%) showed varied performance [1] - The gross margin and net margin for H1 2025 increased by 3.8 and 4.3 percentage points year-on-year, respectively, driven by a higher revenue share from high-margin segments [1] Strategic Developments - The company plans to invest 1.15 billion yuan in a high-end materials industrial park for life sciences in Pucheng, Shaanxi, expanding its capital expenditure in high-ROE sectors [2] - The product range will include chromatography media, polymer chromatography fillers, enzyme carriers, and ultra-pure water-grade adsorption separation materials, marking a deeper strategic shift from industrial to pharmaceutical sectors [2] - Key focus areas for the second half of the year include lithium and life sciences, with significant developments expected in lithium business projects and commercialization of chromatography media [2] Earnings Forecast and Investment Recommendations - The company is projected to achieve revenues of 3.085 billion, 3.824 billion, and 4.679 billion yuan for 2025-2027, with year-on-year growth rates of 20.78%, 23.98%, and 22.34% respectively [3] - Net profit attributable to shareholders is expected to reach 959 million, 1.204 billion, and 1.548 billion yuan for the same period, with growth rates of 21.85%, 25.55%, and 28.53% respectively [3] - The current stock price corresponds to P/E ratios of 28.29, 22.54, and 17.53 for 2025-2027, indicating potential for valuation re-rating as the company transitions towards higher value-added pharmaceutical sectors [3]